Federal Supply Schedule 36F79724D0039

Mitsubishi Tanabe Pharma America, Inc. (UEI: C9L7DNEYYNR3) was awarded a multiple-award Federal Supply Schedule contract under the General Services Administration's Pharmaceuticals and Drugs schedule (FSS-61-IB) effective January 1, 2024, with a contract ceiling of $532 million and completion date of December 31, 2028. This civilian contract, funded by the Department of Veterans Affairs' Veterans Integrated Service Network 12, covers pharmaceutical and hematology-related products classified under Federal Supply Group 65, Item Class 65IB. The contract includes Special Item Number (SIN) 42-2A provisions, which address product deletion and transfer requirements. No set-aside restrictions apply to this contract, and it was awarded without a specific competition limitation, allowing the Veterans Integrated Service Network 12 to procure covered pharmaceutical products at established Federal Supply Schedule pricing.

Under this indefinite delivery vehicle, Mitsubishi Tanabe Pharma America, Inc. will supply drugs, pharmaceuticals, and hematology-related products to support the Veterans Integrated Service Network 12's healthcare operations and the broader Department of Veterans Affairs patient population. The contract structure enables the VA facility to issue task orders for needed pharmaceutical inventory and hematology products at prices established in the Federal Supply Schedule, with the $532 million ceiling representing the maximum contract value through the four-year performance period. This arrangement provides the VA with flexible acquisition authority to obtain essential medications and specialized pharmaceutical products while leveraging the economies of scale and pre-negotiated pricing established through the GSA Federal Supply Schedule framework.